We also measured the plasma concentration of SPON2 in the plasma of prostate cancer and benign prostatic hyperplasia, while no significant differences were observed comparing with the healthy donors, due possibly to the limited number of samples analyzed. Here, SPON2 is linked to benign prostatic hyperplasia.